Amyotrophic lateral sclerosis

Lancet

Volumn 369, Issue 9578, 2007, Pages 2031-2041

  Mitchell, JD ^a   Borasio, GD ^b  

^a ROYAL PRESTON HOSPITAL   (United Kingdom)

^b Department of Neurology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMITRIPTYLINE; ARUNDIC ACID; BACLOFEN; BETA1A INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBAMAZEPINE; CILIARY NEUROTROPHIC FACTOR; CREATINE; DEXTROMETHORPHAN; GLATIRAMER; GLYCOPYRRONIUM BROMIDE; LAMOTRIGINE; LORAZEPAM; MAGNESIUM; MEMANTINE; MINOCYCLINE; MORPHINE; PENTOXIFYLLINE; PHENYTOIN; QUINIDINE; QUININE SULFATE; RECOMBINANT SOMATOMEDIN C; RILUZOLE; SCOPOLAMINE; TETRAZEPAM; TIZANIDINE; TOPIRAMATE; UNINDEXED DRUG; XALIPRODEN;

AMYOTROPHIC LATERAL SCLEROSIS; BEREAVEMENT; CLINICAL TRIAL; DRUG DOSE TITRATION; DYSARTHRIA; DYSPHAGIA; DYSPNEA; FASCICULATION; GENE THERAPY; HUMAN; HYPERSALIVATION; MENTAL DISEASE; MUSCLE CRAMP; OXIDATIVE STRESS; PALLIATIVE THERAPY; PATHOLOGICAL CRYING; PATHOLOGICAL LAUGHTER; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RESPIRATORY TRACT DISEASE; REVIEW; SPASTICITY; SPIRITUAL CARE; STEM CELL TRANSPLANTATION;

EID: 34250209501     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60944-1     Document Type: Review

References (117)

1. Neary D., Snowden J., and Mann D. Cognitive change in motor neurone disease/amyotrophic lateral sclerosis (ALS/ALS). J Neurol Sci 180 (2000) 15-20
2. Gordon P., Cheng B., Katz I., et al. The natural history of primary lateral sclerosis. Neurology 66 (2006) 647-653
3. Kennedy W., Alter M., and Sung J. Progressive proximal spinal and bulbar muscular atrophy of late onset: a sex-linked recessive trait. Neurology 18 (1968) 671-680
4. van Schaik I., van den Berg L., de Haan R., and Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2 (2005) CD004429.
5. Umapathi T., Hughes R., Nobile-Orazio E., and Léger J. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev 3 (2005) CD003217.
6. Ince P., and Codd G. Return of the cycad hypothesis: does the amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC) of Guam have new implications for global health?. Neuropathol Appl Neurobiol 31 (2005) 345-353
7. Haverkamp L., Appel V., and Appel S. Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model for survival prediction. Brain 118 (1995) 707-719
8. Armon C. Environmental risk factors for amyotrophic lateral sclerosis. Neuroepidemiology 20 (2001) 2-69
9. Mitchell J. Amyotrophic lateral sclerosis: toxins and environment. Amyotroph Lateral Scler Other Motor Neuron Disord 1 (2000) 235-250
10. Chio A., Benzi G., Dossena M., Mutani R., and Mora G. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain 128 (2005) 472-476
11. Weisskopf M., O'Reilly E., McCullough M., et al. Prospective study of military service and mortality from ALS. Neurology 64 (2005) 32-37
12. Weisskopf M., McCullough M., Calle E., Thun M., Cudkowicz M., and Ascherio A. Prospective study of cigarette smoking and amyotrophic lateral sclerosis. Am J Epidemiol 160 (2004) 26-33
13. Qureshi M., Hayden D., Urbinelli L., et al. Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS). Amyotrophic Lateral Sclerosis 7 (2006) 173-182
14. Figlewicz D., and Orrell R. The genetics of motor neuron diseases. Amyotroph Lateral Scler Other Motor Neuron Disord 4 (2003) 225-231
15. Parkinson N., Ince P., Smith M., et al. ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). Neurology 67 (2006) 1074-1077
16. World Federation of Neurology Research Group on Neuromuscular Diseases Subcommittee on Motor Neuron Disease. The El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 124 suppl (1994) 96-107
17. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. http://www.wfnals.org/guidelines/1998elescorial/elescorial1998.htm (accessed Feb 18, 2007).
18. Hillel A., Miller R., Yorkston K., McDonald E., Norris F., and Konikow N. Amyotrophic lateral sclerosis severity scale. Neuroepidemiology 8 (1989) 142-150
19. Appel V., Stewart S., Smith G., and Appel S. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 22 (1987) 328-333
20. ALS CNTF treatment study (ACTS) phase I-II study group. The amyotrophic lateral sclerosis functional rating scale: assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 53 (1996) 141-147
21. Ware J., and Sherbourne C. A 36-item short-form health survey (SF-36): conceptual framework and item selection. Med Care 30 (1992) 473-483
22. Jenkinson C., Levvy G., Fitzpatrick R., and Garratt A. The amyotrophic lateral sclerosis assessment questionnaire (ALSAQ-40): tests of data quality, score reliability and response rate in a survey of patients. J Neurol Sci 180 (2000) 94-100
23. Neudert C., Wasner M., and Borasio G. Patients' assessment of quality of life instruments: a randomised study of SIP, SF-36 and SEIQoL-DW in patients with amyotrophic lateral sclerosis. J Neurol Sci 191 (2001) 103-109
24. Simmons Z., Bremer B., Robbins R., et al. Quality of life in ALS depends on factors other than strength and physical function. Neurology 55 (2000) 388-392
25. Murphy P., Albert S., Weber C., et al. Impact of spirituality and religiousness on outcomes in patients with ALS. Neurology 55 (2000) 1581-1584
26. Neudert C., Wasner M., and Borasio G. Individual quality of life is not correlated with health-related quality of life or physical function in patients with amyotrophic lateral sclerosis. J Palliat Med 7 (2004) 551-557
27. Mitchell J. Heavy metals and trace elements in amyotrophic lateral sclerosis. Neurol Clin 5 (1987) 43-60
28. Armon C. An evidence-based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis. Neuroepidemiology 22 (2003) 217-228
29. Miller R., Mitchell J., Lyon M., and Moore D. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 1 (2007) CD001447.
30. Orrell R., Lane R., and Ross M. Antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 1 (2005) CD002829.
31. 2+, mitochondria and selective motoneuron vulnerability: implications for ALS. Trends Neurosci 28 (2005) 494-500
32. Chevalier-Larsen E., and Holzbaur E. Axonal transport and neurodegenerative disease. Biochim Biophys Acta 1762 (2006) 1094-1108
33. Strong M., Kesavapany S., and Pant H. The pathobiology of amyotrophic lateral sclerosis: a proteinopathy?. J Neuropathol Exp Neurol 64 (2005) 649-664
34. Mitchell J., Jackson M., and Pentland B. Indices of free radical activity in the cerebrospinal fluid in motor neurone disease. J Neurol Neurosurg Psychiat 50 (1987) 919-922
35. Rosen D., Siddique T., Patterson D., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993) 59-62
36. Jones C., Swingler R., Simpson S., and Brock D. Superoxide dismutase mutations in an unselected cohort of Scottish amyotrophic lateral sclerosis patients. J Med Genet 32 (1995) 290-292
37. Ceroni M., Malaspina A., Poloni T., et al. Clustering of ALS patients in central Italy due to the occurrence of the L84F SOD1 gene mutation. Neurology 53 (1999) 1064-1071
38. Silahtaroglu A., Brondum-Nielsen K., Gredal O., et al. Human CCS gene: genomic organization and exclusion as a candidate for amyotrophic lateral sclerosis (ALS). BMC Genet 3 (2002) 5
39. Andersen P. Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Curr Neurol Neurosci Rep 6 (2006) 37-46
40. Bacman S., Bradley W., and Moraes C. Mitochondrial involvement in amyotrophic lateral sclerosis: trigger or target?. Mol Neurobiol 33 (2006) 113-131
41. Alexianu M., Ho B., Mohamed A., La Bella V., Smith R., and Appel S. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol 36 (1994) 846-858
42. Neumann M., Sampathu D., Kwong L., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314 (2006) 130-133
43. Mitchell J., Wokke J., and Borasio G. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 3 (2002) CD002064.
44. Bongioanni P., Reali C., and Sogos V. Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 3 (2004) CD004302.
45. The BDNF Study Group (Phase III). A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 52 (1999) 1427-1433
46. Ochs G., Penn R., York M., et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1 (2000) 201-206
47. Meininger V., Bensimon G., Bradley W., et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord 5 (2004) 107-117
48. de Paulis T. ONO-2506 (Ono). Curr Opin Investig Drugs 4 (2003) 863-867
49. Gordon P., Moore D., Gelinas D., et al. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 62 (2004) 1845-1847
50. Pontieri F., Ricci A., Pellicano C., Benincasa D., and Buttarelli F. Minocycline in amyotrophic lateral sclerosis: a pilot study. Neurol Sci 26 (2005) 285-287
51. Ryberg H., Askmark H., and Persson L. A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurol Scand 108 (2003) 1-8
52. Gordon P., Doorish C., Montes J., et al. Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology 66 (2006) 1117-1119
53. Orrell R. AEOL-10150 (Aeolus). Curr Opin Investig Drugs 7 (2006) 70-80
54. Meininger V., Asselain B., Guillet P., et al. Pentoxifylline in ALS: a double-blind, randomized, multicentre, placebo-controlled trial. Neurology 66 (2006) 88-92
55. Groeneveld G., Veldink J., van der Tweel I., et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 53 (2003) 437-445
56. Desnuelle C., Dib M., Garrel C., and Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2 (2001) 9-18
57. Cudkowicz M., Shefner J., Schoenfeld D., et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 61 (2003) 456-464
58. Miller R., Moore II D., Gelinas D., et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 56 (2001) 843-848
59. Beghi E., Chio A., Inghilleri M., et al. A randomized controlled trial of recombinant interferon beta-1a in ALS. Neurology 54 (2000) 469-474
60. Anon. Riluzole (monograph). In: Dollery C. (Ed). Therapeutic drugs. 2nd edn. (1999), Churchill Livingstone, Edinburgh R37-R41
61. Bensimon G., Lacomblez L., and Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330 (1994) 585-591
62. Lacomblez L., Bensimon G., Leigh P., Guillet P., and Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347 (1996) 1425-1431
63. National Institute for Clinical Excellence. Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease: technology appraisal guidance 20, January 2001. Available from: http://www.nice.org.uk/page.aspx?o=ta020 (accessed Feb 18, 2007).
64. Mitchell J., O'Brien M., and Joshi M. Audit of outcomes in motor neuron disease (MND) patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord 7 (2006) 67-71
65. Oliver D., Borasio G., and Walsh D. Palliative care in amyotrophic lateral sclerosis: from diagnosis to bereavement. 2nd edn. (2006), Oxford University Press, Oxford
66. Miller R., Rosenberg J., Gelinas D., et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review)-report of the Quality Standards Subcommittee of the American Academy of Neurology, ALS Practice Parameters Task Force. Neurology 52 (1999) 1311-1323
67. Andersen P., Borasio G., Dengler R., et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives: an evidence-based review with good practice points. Eur J Neurol 12 (2005) 921-938
68. Mitsumoto H., Bromberg M., Johnston W., et al. Promoting excellence in end-of-life care in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 6 (2005) 145-154
69. Simmons Z. Management strategies for patients with amyotrophic lateral sclerosis from diagnosis through death. Neurologist 11 (2005) 257-270
70. Borasio G., Shaw P., Hardiman O., et al. Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey. Amyotroph Lateral Scler Other Motor Neuron Disord 2 (2001) 159-164
71. Van den Berg J., Kalmijn S., Lindeman E., et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology 65 (2005) 1264-1267
72. Borasio G., Voltz R., and Miller R. Palliative care in amyotrophic lateral sclerosis. Neurol Clin 19 (2001) 829-847
73. McMurray A., and Harris A. Bereavement. In: Oliver D., Borasio G., and Walsh D. (Eds). Palliative care in amyotrophic lateral sclerosis: from diagnosis to bereavement. 2nd edn. (2006), Oxford University Press, Oxford 301-323
74. Borasio G., Sloan R., and Pongratz D. Breaking the news in amyotrophic lateral sclerosis. J Neurol Sci 160 (1998) 127-133
75. Wasner M., Klier H., and Borasio G. The use of alternative medicine by patients with amyotrophic lateral sclerosis. J Neurol Sci 191 (2001) 151-154
76. Neudert C., Oliver D., Wasner M., and Borasio G. The course of the terminal phase in patients with amyotrophic lateral sclerosis. J Neurol 248 (2001) 612-616
77. Borasio G., and Voltz R. Advance directives. In: Oliver D., Borasio G., and Walsh D. (Eds). Palliative care in amyotrophic lateral sclerosis: from diagnosis to bereavement. 2nd edn. (2006), Oxford University Press, Oxford 55-61
78. Silverstein M., Stocking C., Antel J., et al. Amyotrophic lateral sclerosis and life-sustaining therapy: patients' desires for information, participation in decision making, and life-sustaining therapy. Mayo Clin Proc 66 (1991) 906-913
79. Wagner-Sonntag E., and Prosiegel M. Dysphagia. In: Oliver D., Borasio G., and Walsh D. (Eds). Palliative care in amyotrophic lateral sclerosis: from diagnosis to bereavement. 2nd edn. (2006), Oxford University Press, Oxford 95-109
80. Kasarskis E., Scarlata D., Hill R., Fuller C., Stambler N., and Cedarbaum J. A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials. J Neurol Sci 169 (1999) 118-125
81. Gregory S., Siderowf A., Golaszewski A., and McCluskey L. Gastrostomy insertion in ALS patients with low vital capacity: respiratory support and survival. Neurology 58 (2002) 485-487
82. Chio A., Galletti R., Finocchiaro C., et al. Percutaneous radiological gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS. J Neurol Neurosurg Psychiatry 75 (2004) 645-647
83. Scott A., and McPhee M. Speech and language therapy. In: Oliver D., Borasio G., and Walsh D. (Eds). Palliative care in amyotrophic lateral sclerosis: from diagnosis to bereavement. 2nd edn. (2006), Oxford University Press, Oxford 213-227
84. Kubler A., Nijboer F., Mellinger J., et al. Patients with ALS can use sensorimotor rhythms to operate a brain-computer interface. Neurology 64 (2005) 1775-1777
85. Sykes N., and Thorns A. The use of opioids and sedatives at the end of life. Lancet Oncol 4 (2003) 312-318
86. Lyall R., and Gelinas D. Dyspnoea and respiratory problems. In: Oliver D., Borasio G., and Walsh D. (Eds). Palliative care in amyotrophic lateral sclerosis: from diagnosis to bereavement. 2nd edn. (2006), Oxford University Press, Oxford 63-93
87. Bourke S., Tomlinson M., Williams T., Bullock R., Shaw P., and Gibson G. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 5 (2006) 140-147
88. Mustfa N., Walsh E., Bryant V., et al. The effect of non-invasive ventilation on ALS patients and their caregivers. Neurology 66 (2006) 1211-1217
89. Kleopa K., Sherman M., Neal B., Romano G., and Heiman-Patterson T. Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci 164 (1999) 82-88
90. American Academy of Neurology. Assisted suicide, euthanasia, and the neurologist. Neurology 50 (1998) 596-598
91. Borasio G., and Voltz R. Discontinuation of life support in patients with amyotrophic lateral sclerosis. J Neurol 245 (1998) 717-722
92. Sancho J., Servera E., Diaz J., and Marin J. Efficacy of mechanical insufflation-exsufflation in medically stable patients with amyotrophic lateral sclerosis. Chest 125 (2004) 1400-1405
93. Ganzini L., Johnston W., McFarland B., et al. Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide. N Engl J Med 339 (1998) 967-973
94. Rabkin J., Albert S., Del Bene M., et al. Prevalence of depressive disorders and change over time in late-stage ALS. Neurology 65 (2005) 62-67
95. Rabkin J., Wagner G., and Del Bene M. Resilience and distress among amyotrophic lateral sclerosis patients and caregivers. Psychosom Med 62 (2000) 271-279
96. Brooks B., Thisted R., Appel S., et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 63 (2004) 1364-1370
97. Giess R., Naumann M., Werner E., et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 69 (2000) 121-123
98. Stalpers L., and Moser E. Results of radiotherapy for drooling in amyotrophic lateral sclerosis. Neurology 58 (2002) 1308
99. Oliver D. The quality of care and symptom control: the effects on the terminal phase of ALS/MND. J Neurol Sci 139 suppl (1996) 134-136
100. Newrick P., and Langton-Hewer R. Pain in motor neuron disease. J Neurol Neurosurg Psychiatry 48 (1985) 838-840
101. Veldink J., Wokke J., van der Wal G., Vianney de Jong J., and van den Berg L. Euthanasia and physician-assisted suicide among patients with amyotrophic lateral sclerosis in the Netherlands. N Engl J Med 346 (2002) 1638-1644
102. Gallagher D., and Monroe B. Psychosocial care. In: Oliver D., Borasio G., and Walsh D. (Eds). Palliative care in amyotrophic lateral sclerosis: from diagnosis to bereavement. 2nd edition (2006), Oxford University Press, Oxford 143-168
103. Lambert R. Spiritual care. In: Oliver D., Borasio G., and Walsh D. (Eds). Palliative care in amyotrophic lateral sclerosis: from diagnosis to bereavement. 2nd edn. (2006), Oxford University Press, Oxford 169-185
104. O'Brien T., Kelly M., and Saunders C. Motor neurone disease: a hospice perspective. BMJ 304 (1992) 471-473
105. de Carvalho M., Chio A., Dengler R., Hecht M., Weber M., and Swash M. Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials. Amyotroph Lateral Scler Other Motor Neuron Disord 6 (2005) 17-28
106. Mills K. The natural history of central motor abnormalities in amyotrophic lateral sclerosis. Brain 126 (2003) 2558-2566
107. Aoki S., Iwata N., Masutani Y., et al. Quantitative evaluation of the pyramidal tract segmented by diffusion tensor tractography: feasibility study in patients with amyotrophic lateral sclerosis. Radiat Med 23 (2005) 195-199
108. Kaspar B., Llado J., Sherkat N., Rothstein J., and Gage F. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301 (2003) 839-842
109. Azzouz M., Ralph G., Storkebaum E., et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429 (2004) 413-417
110. Storkebaum E., Lambrechts D., Dewerchin M., et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 8 (2005) 85-92
111. Silani V., and Corbo M. Cell-replacement therapy with stem cells in neurodegenerative diseases. Curr Neurovasc Res 1 (2004) 283-289
112. Silani V., Cova L., Corbo M., Ciammola A., and Polli E. Stem-cell therapy for amyotrophic lateral sclerosis. Lancet 364 (2004) 200-202
113. Mazzini L., Fagioli F., Boccaletti R., et al. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotroph Lateral Scler Other Motor Neuron Disord 4 (2003) 158-161
114. Silani V., and Leigh N. Stem therapy for ALS: hope and reality. Amyotroph Lateral Scler Other Motor Neuron Disord 4 (2003) 8-10
115. Appel S., Engelhardt J., Henkel J., et al. Allogeneic haematopoietic stem cell transplantation in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 5 suppl 2 (2004) 54
116. Bowser R., Cudkowicz M., and Kaddurah-Daouk R. Biomarkers for amyotrophic lateral sclerosis. Expert Rev Mol Diagn 6 (2006) 387-398
117. Federici T., and Boulis N. Gene-based treatment of motor neuron diseases. Muscle Nerve 33 (2006) 302-323